688166 XD博瑞医药
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.5297.9438.88012.38415.688
总资产报酬率 ROA (%)0.2483.7114.1786.28010.170
投入资产回报率 ROIC (%)0.2714.0154.5036.91011.259

边际利润分析
销售毛利率 (%)43.94657.51055.79463.01156.227
营业利润率 (%)-4.77812.49816.12923.80324.609
息税前利润/营业总收入 (%)-0.44815.44718.05124.77125.009
净利润/营业总收入 (%)-1.87011.01414.70320.78322.573

收益指标分析
经营活动净收益/利润总额(%)148.351114.473105.52296.612102.124
价值变动净收益/利润总额(%)-5.138-11.026-8.0840.2323.892
营业外收支净额/利润总额(%)-0.274-1.965-0.7810.021-0.597

偿债能力分析
流动比率 (X)1.6751.5591.9952.3881.703
速动比率 (X)1.2851.2121.6212.0431.360
资产负债率 (%)50.50452.80451.95451.90841.351
带息债务/全部投入资本 (%)45.80747.10647.83648.34135.207
股东权益/带息债务 (%)112.987107.386105.609105.323181.201
股东权益/负债合计 (%)93.72087.81390.60490.579136.663
利息保障倍数 (X)-0.1044.8438.82025.71645.853

营运能力分析
应收账款周转天数 (天)109.27485.71789.395119.63694.175
存货周转天数 (天)235.490234.266215.752229.802157.568